Cannabidiol‐Rich Cannabis sativa L. Extract Alleviates LPS‐Induced Neuroinflammation Behavioral Alterations, and Astrocytic Bioenergetic Impairment in Male Mice
- 8 April 2025
- journal article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (4) , e70035
Abstract
Neuroinflammation is a hallmark of various neurodegenerative disorders, yet effective treatments remain limited. This study investigates the neuroprotective potential of a cannabidiol (CBD)‐Rich Cannabis sativa L. (CS) extract in a lipopolysaccharide (LPS)‐induced neuroinflammation mouse model. The effects on anxiety‐like behavior, cognitive function, and locomotor activity were assessed using behavioral tests (open field, elevated plus maze, novel object recognition, and Morris water maze). Antioxidant activity was measured by assaying glutathione (GSH) levels and lipid peroxidation by‐products (TBARs). Anti‐inflammatory properties were evaluated using quantitative reverse transcription polymerase chain reaction (QRt‐PCR) for proinflammatory cytokines (IL‐6 and TNF‐α), glial fibrillary acidic protein (GFAP), and cannabinoid receptor 1 (CB1) mRNAs in the prefrontal cortex (PFC). Astrocytic bioenergetics were analyzed using extracellular flux assays. Additionally, computational inference with a deep learning approach was conducted to evaluate the synergistic interactions among CS phytocompounds on the CB1 receptors. Compared with synthetic CBD, the CS extract (20.0 mg/kg) demonstrated superior efficacy in mitigating LPS‐induced anxiety‐like behavior, cognitive deficits, and locomotor impairments. It also significantly mitigated oxidative stress (increased GSH, reduced TBARs) and suppressed proinflammatory cytokines and GFAP mRNAs, indicating potent anti‐inflammatory properties. The extract modulated CB1 receptor expression and preserved metabolic homeostasis in cortical astrocytes, preventing their shift from glycolysis to oxidative phosphorylation under neuroinflammatory conditions. Computational modeling highlighted conformational changes in CB1 receptor residues induced by Delta‐9‐THC that enhanced CBD binding. These findings underscore the potential of CS extract as a therapeutic candidate for managing neuroinflammation and its associated neurodegenerative consequences, warranting further clinical exploration.Keywords
This publication has 102 references indexed in Scilit:
- Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI AnalysisChemMedChem, 2024
- Endocannabinoid signaling in astrocytesGlia, 2022
- Non‐psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors‐, endocannabinoids‐, and NF‐κB‐mediated signalingPhytotherapy Research, 2022
- Hydrogen Sulfide Ameliorates Lipopolysaccharide-Induced Memory Impairment in Mice by Reducing Apoptosis, Oxidative, and Inflammatory EffectsNeurotoxicity Research, 2021
- The metabolic response to inflammation in astrocytes is regulated by nuclear factor‐kappa B signalingGlia, 2020
- Current Status and Prospects for Cannabidiol Preparations as New Therapeutic AgentsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARsMolecular Neurobiology, 2016
- Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned MiceNeurotherapeutics, 2015
- Astrocytic glycogenolysis: mechanisms and functionsMetabolic Brain Disease, 2014
- The use of a plus-maze to measure anxiety in the mousePsychopharmacology, 1987